Due to the promising efficacy of pembrolizumab, the US Food and Drug Administration (FDA) approved it as the first-line therapy for PD-L1 ≥ 1% tumor cells, and European Medicines Agency (EMA) approved it for tumors with PD-L1 expression ≥ 50%. This evidence concerns the gene CD274 and neoplasm.